BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 28265738)

  • 21. MicroPET/CT imaging of patient-derived pancreatic cancer xenografts implanted subcutaneously or orthotopically in NOD-scid mice using (64)Cu-NOTA-panitumumab F(ab')2 fragments.
    Boyle AJ; Cao PJ; Hedley DW; Sidhu SS; Winnik MA; Reilly RM
    Nucl Med Biol; 2015 Feb; 42(2):71-7. PubMed ID: 25456837
    [TBL] [Abstract][Full Text] [Related]  

  • 22. (89)Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft.
    Oude Munnink TH; Korte MA; Nagengast WB; Timmer-Bosscha H; Schröder CP; Jong JR; Dongen GA; Jensen MR; Quadt C; Hooge MN; Vries EG
    Eur J Cancer; 2010 Feb; 46(3):678-84. PubMed ID: 20036116
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of (89)Zr-pertuzumab in Breast cancer xenografts.
    Marquez BV; Ikotun OF; Zheleznyak A; Wright B; Hari-Raj A; Pierce RA; Lapi SE
    Mol Pharm; 2014 Nov; 11(11):3988-95. PubMed ID: 25058168
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies.
    Faratian D; Zweemer AJ; Nagumo Y; Sims AH; Muir M; Dodds M; Mullen P; Um I; Kay C; Hasmann M; Harrison DJ; Langdon SP
    Clin Cancer Res; 2011 Jul; 17(13):4451-61. PubMed ID: 21571868
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ImmunoPET for assessing the differential uptake of a CD146-specific monoclonal antibody in lung cancer.
    Sun H; England CG; Hernandez R; Graves SA; Majewski RL; Kamkaew A; Jiang D; Barnhart TE; Yang Y; Cai W
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2169-2179. PubMed ID: 27342417
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PET Imaging of Tissue Factor in Pancreatic Cancer Using 64Cu-Labeled Active Site-Inhibited Factor VII.
    Nielsen CH; Jeppesen TE; Kristensen LK; Jensen MM; El Ali HH; Madsen J; Wiinberg B; Petersen LC; Kjaer A
    J Nucl Med; 2016 Jul; 57(7):1112-9. PubMed ID: 27013699
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Imaging and biodistribution of Her2/neu expression in non-small cell lung cancer xenografts with Cu-labeled trastuzumab PET.
    Paudyal P; Paudyal B; Hanaoka H; Oriuchi N; Iida Y; Yoshioka H; Tominaga H; Watanabe S; Watanabe S; Ishioka NS; Endo K
    Cancer Sci; 2010 Apr; 101(4):1045-50. PubMed ID: 20219072
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts.
    McLarty K; Cornelissen B; Cai Z; Scollard DA; Costantini DL; Done SJ; Reilly RM
    J Nucl Med; 2009 Aug; 50(8):1340-8. PubMed ID: 19617342
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the first
    Honarvar H; Müller C; Cohrs S; Haller S; Westerlund K; Karlström AE; van der Meulen NP; Schibli R; Tolmachev V
    Nucl Med Biol; 2017 Feb; 45():15-21. PubMed ID: 27837664
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PET imaging of a
    Xu Y; Wang L; Pan D; Yu C; Mi B; Huang Q; Sheng J; Yan J; Wang X; Yang R; Yang M
    Br J Radiol; 2019 Dec; 92(1104):20190425. PubMed ID: 31593482
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET.
    Mortimer JE; Bading JR; Colcher DM; Conti PS; Frankel PH; Carroll MI; Tong S; Poku E; Miles JK; Shively JE; Raubitschek AA
    J Nucl Med; 2014 Jan; 55(1):23-9. PubMed ID: 24337604
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 64Cu-labeled affibody molecules for imaging of HER2 expressing tumors.
    Cheng Z; De Jesus OP; Kramer DJ; De A; Webster JM; Gheysens O; Levi J; Namavari M; Wang S; Park JM; Zhang R; Liu H; Lee B; Syud FA; Gambhir SS
    Mol Imaging Biol; 2010 Jun; 12(3):316-24. PubMed ID: 19779897
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Influence of Glycans-Specific Bioconjugation on the FcγRI Binding and
    Vivier D; Fung K; Rodriguez C; Adumeau P; Ulaner GA; Lewis JS; Sharma SK; Zeglis BM
    Theranostics; 2020; 10(4):1746-1757. PubMed ID: 32042334
    [No Abstract]   [Full Text] [Related]  

  • 34. Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies.
    Terwisscha van Scheltinga AG; van Dam GM; Nagengast WB; Ntziachristos V; Hollema H; Herek JL; Schröder CP; Kosterink JG; Lub-de Hoog MN; de Vries EG
    J Nucl Med; 2011 Nov; 52(11):1778-85. PubMed ID: 21990576
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Small-animal SPECT/CT of HER2 and HER3 expression in tumor xenografts in athymic mice using trastuzumab Fab-heregulin bispecific radioimmunoconjugates.
    Razumienko EJ; Scollard DA; Reilly RM
    J Nucl Med; 2012 Dec; 53(12):1943-50. PubMed ID: 23096164
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Three methods for 18F labeling of the HER2-binding affibody molecule Z(HER2:2891) including preclinical assessment.
    Glaser M; Iveson P; Hoppmann S; Indrevoll B; Wilson A; Arukwe J; Danikas A; Bhalla R; Hiscock D
    J Nucl Med; 2013 Nov; 54(11):1981-8. PubMed ID: 24115530
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [
    Lu Y; Li M; Massicano AVF; Song PN; Mansur A; Heinzman KA; Larimer BM; Lapi SE; Sorace AG
    Molecules; 2021 Mar; 26(6):. PubMed ID: 33809310
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts.
    Malmberg J; Perols A; Varasteh Z; Altai M; Braun A; Sandström M; Garske U; Tolmachev V; Orlova A; Karlström AE
    Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):481-92. PubMed ID: 22322933
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PET imaging of CD105/endoglin expression with a ⁶¹/⁶⁴Cu-labeled Fab antibody fragment.
    Zhang Y; Hong H; Orbay H; Valdovinos HF; Nayak TR; Theuer CP; Barnhart TE; Cai W
    Eur J Nucl Med Mol Imaging; 2013 May; 40(5):759-67. PubMed ID: 23344138
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dual-labeled pertuzumab for multimodality image-guided ovarian tumor resection.
    Lee HJ; Ehlerding EB; Jiang D; Barnhart TE; Cao T; Wei W; Ferreira CA; Huang P; Engle JW; Cai W
    Am J Cancer Res; 2019; 9(7):1454-1468. PubMed ID: 31392081
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.